^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Cutaneous Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    J Clin Oncol
    Published date:
    03/31/2020
    Excerpt:
    Recommendation 3.2….For patients with BRAF-mutant (V600) unresectable/metastatic cutaneous melanoma, the following treatment options should be offered (in no particular order)...vemurafenib plus cobimetinib…
    DOI:
    10.1200/JCO.20.00198
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

    Excerpt:
    ...Documented BRAFV600 mutation determined in a hospital center specializing in the molecular genetics of cancer that is certified by the French national cancer institute (INCa)....
    Trial ID:
    CONVERCE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

    Excerpt:
    ...- Documentation of BRAF V600 test result mutation-positive status on melanoma tumor tissue using a validated tissue test...
    Trial ID:
    NCT02768207